AMERICAN SOCIETY FOR MICROBIOLOGY | Antimicrobial Agents and Chemotherapy®

PHARMACOLOGY

Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis

S. Deng,[a] W. Lei,[b] G. S. de Hoog,[b,c,d,e] L. Yang,[c] R. G. Vitale,[f] H. Rafati,[g] M. Seyedmousavi,[g] A. Tolooe,[g] H. van der Lee,[e] W. Liao,[b] P. E. Verweij,[e] S. Seyedmousavi[e,g,h]*

[a]Department of Medical Microbiology, People's Hospital of Suzhou National New & Hi-Tech Industrial Development Zone, Jiangsu, China

[b]Shanghai Institute of Medical Mycology, Department of Dermatology, Changzheng Hospital, Second Military Medical University, Shanghai, China

[c]Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands

[d]Basic Pathology Department, Federal University of Paraná State, Curitiba, Paraná, Brazil

[e]Department of Medical Microbiology, Radboud University Medical Center, and Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands

[f]CONICET and Ramos Mejia Hospital, Parasitology Unit, Mycology Section, Buenos Aires, Argentina

[g]Center of Excellence for Infection Biology and Antimicrobial Pharmacology, Tehran, Iran

[h]Invasive Fungi Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

ABSTRACT Our *in vitro* studies showed that a combination of amphotericin B and terbinafine had synergistic effects against the majority of melanized fungi associated with chromoblastomycosis (CBM) and similar infections, including those with *Cladophialophora carrionii*, *Cladophialophora arxii*, *Exophiala dermatitidis*, *Exophiala spinifera*, *Fonsecaea monophora*, *Fonsecaea nubica*, *Fonsecaea pedrosoi*, and *Phialophora verrucosa*. This drug combination could provide an option for the treatment of severe or unresponsive cases of CBM, particularly in cases due to species of *Fonsecaea* and *Cladophialophora*.

KEYWORDS combination therapy, amphotericin B, terbinafine, melanized fungi, chromoblastomycosis

Chromoblastomycosis (CBM) is a serious fungal skin disease associated with significant morbidity (1). The disease is characterized histologically by muriform cells that cause chronic inflammation of the skin and subcutaneous tissues (2, 3). The infection leads to excessive proliferation of host tissue, formation of cauliflower-like eruptions on the skin, or hyperkeratosis, or it may exhibit intermediate forms, depending on the type of interaction between host and fungal cells (4, 5). Because of chronicity, the CBM lesions may also undergo neoplastic transformation leading to skin cancer (6). The chronic nature of the infections seems to be due to inadequate innate recognition and subsequent failure to mount protective inflammatory responses (7).

The disease has worldwide distribution, mainly in tropical and subtropical climates (8). Species in humid climates, particularly members of the genus *Fonsecaea* (*F. pedrosoi*, *F. monophora*, and *F. nubica*), are prevalent agents of CBM (9). *Cladophialophora carrionii* is the predominant agent of the disease under arid desert-like climate conditions (10). Sporadic cases of CBM-like infections have also been reported for *Cladophialophora arxii* (11), *Exophiala dermatitidis* (12), *Exophiala spinifera* (13), *Phialophora verrucosa* (14), and *Veronaea botryose* (15), although attribution to this disease category has not been confirmed.

CBM is extremely difficult to treat due to its recalcitrant nature, and there is no consensus regarding the treatment of choice (16). Based on open clinical studies and expert opinions, itraconazole is the first-line recommended therapy for CBM (17),

Received 8 February 2018 **Returned for modification** 2 March 2018 **Accepted** 15 March 2018

Accepted manuscript posted online 26 March 2018

Citation Deng S, Lei W, de Hoog GS, Yang L, Vitale RG, Rafati H, Seyedmousavi M, Tolooe A, van der Lee H, Liao W, Verweij PE, Seyedmousavi S. 2018. Combination of amphotericin B and terbinafine against melanized fungi associated with chromoblastomycosis. Antimicrob Agents Chemother 62:e00270-18. https://doi.org/10.1128/AAC.00270-18.

Address correspondence to S. Seyedmousavi, Seyedmousavi@nih.gov.

* Present address: S. Seyedmousavi, Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

S.D. and W.L. contributed equally as first author.

followed by terbinafine (18). However, infections by *F. pedrosoi* strains resistant to itraconazole have been reported (19). Cure rates with itraconazole and terbinafine monotherapy may range from 15 to 80%, which on average, is insufficient (20). When possible, the addition of physical therapeutic methods, such as laser and photodynamic therapy, is recommended (21, 22), which is still associated with rather low cure rates and high refractory rates.

Alternative therapeutic strategies employing newer antifungal agents and/or combination of drugs (23–26) might be promising to treat CBM more efficiently. In a recent study, we also demonstrated that amphotericin B in combination with flucytosine may have a role in the treatment of primary cerebral infections caused by other melanized fungi of the order *Chaetothyriales* (27). We therefore sought to investigate the *in vitro* antifungal activity of amphotericin B in combination with terbinafine against a collection of black fungi obtained from patients with CBM.

A collection of 46 isolates of melanized fungi associated with CBM or similar skin infections were studied, including *C. carrionii* ($n = 10$), *C. arxii* ($n = 1$), *Exophiala dermatitidis* ($n = 9$), *E. spinifera* ($n = 3$), *Fonsecaea monophora* ($n = 7$), *F. nubica* ($n = 5$), *F. pedrosoi* ($n = 5$), *Phialophora verrucosa* ($n = 3$), and *Veronaea botryosa* ($n = 3$). The identities of the organisms were confirmed by sequencing of the internal transcribed spacer regions of ribosomal DNA (rDNA), as described previously (28). All isolates were subcultured on malt extract agar (MEA) at 25°C. Conidial suspensions were harvested and suspended in normal saline containing 0.025% Tween 20. Supernatants were adjusted spectrophotometrically at 530-nm wavelengths to optical densities (ODs) that ranged from 0.15 to 0.17 (68 to 71% transmission) for all isolates, except *E. dermatitidis*, whose ODs ranged from 0.09 to 0.13 (80 to 83% transmission), as described previously (27).

Amphotericin B (Sigma-Aldrich, St. Louis, MO, USA) and terbinafine (Novartis, Arnhem, The Netherlands) were obtained as standard pure powders, and serial dilutions were prepared according to the Clinical and Laboratory Standards Institute (CLSI) broth microdilution guidelines (29). Antifungal susceptibility and drug interaction testing were performed by using the broth microdilution checkerboard (2-dimensional, 8-by-12) method (27). The final concentrations of the antifungal agents ranged from 0.125 to 8 μg/ml for amphotericin B and 0.008 to 8 μg/ml for terbinafine. To assess the nature of *in vitro* interactions between amphotericin B and terbinafine, the data obtained were analyzed using nonparametric approaches of the following two no (zero)-interaction theories: Loewe additivity, defined as the fractional inhibitory concentration (FIC), and the Bliss independence (BI) parameter, obtained from response surface analysis (30), as described previously (27). Drug interactions were defined as synergistic if the FIC index was <1, additive if the FIC index was 1, and antagonistic if the FIC index was >1 (31). The BI drug interactions were considered synergistic if ΔE was >0 (positive ΔE), indifferent if ΔE was 0, or antagonistic if ΔE was <0 (negative ΔE) (32). All experiments were performed in three independent replicates on different days. All data analyses were performed by using the software package GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA). A P value of ≤ 0.05 was considered significant (two-tailed).

The mean (range) MICs were 4.46 (0.125 to >8) μg/ml for amphotericin B across all isolates and 0.86 (0.16 to >8) for terbinafine (Table 1). For the amphotericin B and terbinafine combinations, the geometric mean FIC indices, in increasing order, were 0.41 for *F. monophora* ($\sum$FIC range, 0.25 to 0.5), 0.5 for *E. spinifera* ($\sum$FIC range, 0.25 to 1), 0.63 for *E. dermatitidis* ($\sum$FIC range, 0.25 to 1), 0.7 for *C. carrionii* ($\sum$FIC range, 0.5 to 1), 0.72 for *P. verrucosa* ($\sum$FIC range, 0.5 to 1), 0.76 for *F. nubica* ($\sum$FIC range, 0.25 to 1), 0.76 for *F. pedrosoi* ($\sum$FIC range, 0.5 to 1), and 1 for *C. arxii* ($n = 1$), which indicate synergy and additivity for these strains. However, antagonism was noted in *V. botryosa* isolates, with a mean FIC value of 1.4 ($\sum$FIC range, 1 to 2).

The Bliss independence drug interaction analysis for the amphotericin B and terbinafine combination resulted in a synergistic interaction for 71.74% (33/46) of the strains tested. The degree of synergy was the highest among the *C. carrionii* strains (sum ΔE,

TABLE 1 MIC, FIC indices, and Bliss independence results for the *in vitro* combination of AmB and TBF against melanized fungi associated with chromoblastomycosis

Strain no.	Fungal species	Strain	Source	Origin	MIC (μg/ml)[a]		FIC index	Bliss independence index
					TBF	AmB		
1	*Cladophialophora carrionii*	CBS 131844	Human, chromoblastomycosis	China	0.031	1	0.75	111.3
2		CBS 131854	Human, chromoblastomycosis	Madagascar	0.063	8	0.5	69.24
3		CBS 131833	Human, chromoblastomycosis	China	1	8	1	−4.48
4		CBS 131847	Human, chromoblastomycosis	China	0.031	4	0.5	410.73
5		CBS 160.54	Human, chromoblastomycosis	Australia	0.031	1	0.75	−8.29
6		CBS 859.96	Dry plant debris	Venezuela, arid zone west of Coro	0.016	1	0.75	−40.42
7		CBS 863.96	Dry plant debris	Venezuela, arid zone west of Coro	0.016	2	0.75	6.37
8		CBS 131736	Soil	Venezuela, arid zone west of Coro	0.031	4	0.5	75.15
9		CBS 860.96	Dry plant debris	Venezuela, arid zone west of Coro	0.016	4	0.75	893.89
10		CBS 861.96	Dry plant debris	Venezuela, arid zone west of Coro	0.125	8	1	143.51
11	*Cladophialophora arxii*	CBS 102461	Human, brain abscess	USA	0.5	4	1	90.2
12	*Exophiala dermatitidis*	CBS 120542	Human or animal, stool	Slovenia	0.5	4	0.5	138.26
13		CBS 120562	Human, keratitis	USA	0.5	0.25	1	151.7
14		CBS 120473	Human, brain	USA	0.25	0.5	1	−4,736
15		CBS 424.67	Human, chromoblastomycosis	Germany	0.5	0.125	1	−11.78
16		CBS 550.9	Human, sputum, cystic fibrosis	Germany	0.031	2	1	258.1
17		CBS 126590	Human, sputum, cystic fibrosis	The Netherlands	0.5	1	0.25	89.2
18		CBS 120550	Steam bath	Austria	0.5	2	0.5	133.05
19		CBS 120483	Flying fox's feces	Thailand	0.25	4	0.25	346.03
20		CBS 109138	Hall of sauna complex	The Netherlands	0.5	4	1	−43.35
21	*Exophiala spinifera*	CBS 899.68	Human, nasal granuloma	USA	2	2	1	62.94
22		CBS 269.28	Human, chromoblastomycosis	Unknown	0.5	8	0.5	64.9
23		CBS 194.61	Human, systemic mycosis	India	0.5	>8	0.25	450.11
24	*Fonsecaea monophora*	CBS 117236	Human, brain abscess	USA	0.5	8	0.5	305
25		CBS 269.37	Unknown, chromoblastomycosis	Unknown	0.25	8	0.5	209.7
26		CBS 117238	Unknown, brain	England	5	8	0.25	49.7
27		CBS 122742	Human, chromoblastomycosis	China	0.5	8	0.5	14.98
28		CBS 100430	Human, brain	Africa	0.5	8	0.5	311.02
29		CBS 102229	Decaying vegetable	Piraquara, Paraná, Brazil	0.5	4	0.5	27.6
30		CBS 289.93	Animal, lymph node, aspiration biopsy	The Netherlands	8	8	0.25	526.72
31	*Fonsecaea nubica*	CBS 277.29	Human, chromoblastomycosis	Brazil	1	4	1	154.1
32		CBS 444.62	Human, chromoblastomycosis	Suriname	0.5	8	1	−7.07
33		CBS 122733	Human, chromoblastomycosis	China	0.25	4	1	−69.4
34		CBS 269.64	Human, chromoblastomycosis	Cameroon	0.5	8	0.75	−79.6
35		CBS 125198	Human, chromoblastomycosis	China	0.25	8	0.25	−223.17
36		CBS 127264	Human, chromoblastomycosis	Mexico	1	4	1	−271.7
37	*Fonsecaea pedrosoi*	CBS 102247	Human, chromoblastomycosis	Paraná, Brazil	0.5	4	0.5	123.76
38		CBS 285.47	Human, chromoblastomycosis	Puerto Rico	0.5	4	0.5	298.9
39		CBS 122739	Human, chromoblastomycosis	Mexico	0.5	4	1	114.3
40		CBS 117910	Human, chromoblastomycosis	Venezuela	0.5	4	1	297.27
41		CBS 671.66	Soil	Venezuela	0.5	2	1	64.1
42	*Phialophora verrucosa*	CBS 120349	Plant	China	0.5	4	1	123.76
43		CBS 262.93	Exudate from right hand (human or animal)	Germany	0.016	0.5	0.5	52941
44		CBS 115.89	Disseminated (human or animal)	Libya	0.25	8	0.75	−47.99
45	*Veronaea botryosa*	CBS 122826	Railway tie treated with creosote for 20 years	Brazil	1	4	2	−271.7
46		CBS 121506	Cutaneous lesion, wrist	Japan	>8	2	1	160.1

[a]The final concentration range for TBF was 0.008 to 8 μg/ml, and that for AmB was 0.125 to 8 μg/ml.



FIG 1 Interaction surfaces obtained from response surface analysis of Bliss independence no-interaction model for *in vitro* combination of amphotericin B (AmB) plus terbinafine (TBF). The *x* and *y* axis represent the efficacy of AmB and TBF, respectively. The *z* axis is the ΔE (%). The 0-plane represents Bliss independent interactions, whereas the volumes above the 0-plane represent statistically significantly synergistic (positive ΔE) interactions. The magnitude of interactions is directly related to ΔE. The different tones in three dimensional plots represent different percentile bands of synergy. The highest level of synergistic interactions was found between 0.25 μg/ml amphotericin B and terbinafine concentrations in the range of 0.008 to 0.5 μg/ml. (A) Synergistic interaction of AmB plus TBF against an *Exophiala spinifera* strain (CBS 194.61) (AmB MIC, 0.5 μg/ml; TBF MIC, >8 μg/ml). The mean ΔE ± standard error of the mean and sum ΔE were 5.36% ± 1.81% and 450.11%, respectively. The highest level of synergistic interactions was found between 0.25 μg/ml amphotericin B and terbinafine concentrations in the range of 0.008 to 0.5 μg/ml. (B) Antagonistic interaction of AmB plus TBF against a *Veronaea botryosa* strain (CBS 122826) (AmB MIC, 1 μg/ml; TBF MIC, 4 μg/ml). The mean ΔE ± standard error of the mean and sum ΔE were −3.23% ± 1.70% and −271.70%, respectively.

1,546%), followed by *F. monophora* (sum ΔE, 1,140%), *F. pedrosoi* (sum ΔE, 775%), *E. spinifera* (sum ΔE, 515%), *P. verrucosa* (sum ΔE, 481%), *E. dermatitidis* (sum ΔE, 449%), and *C. arxii* (sum ΔE, 90%). The strongest synergistic interactions were found at amphotericin B and terbinafine concentration ranges of 0.125 to 0.5 μg/ml and 0.008 to 0.5 μg/ml, respectively. Examples of Bliss independence 3-dimensional plots for the synergistic and antagonistic interactions of amphotericin B and flucytosine are shown in Fig. 1.

Overall, our results show that the amphotericin B and terbinafine combination has synergistic effects against the majority of melanized fungi associated with CBM, including *C. carrionii*, *C. arxii*, *E. dermatitidis*, *E. spinifera*, *F. monophora*, *F. nubica*, *F. pedrosoi*, and *P. verrucosa*. The results of FIC analysis were supported by response surface analysis using a Bliss independence no-interaction model for the isolates tested.

Terbinafine is one of most commonly used antifungal agents in the treatment of patients with CBM (18), due to its high degree of effectiveness and tolerability. In an athymic murine model of CBM caused by *F. pedrosoi*, terbinafine, especially at the highest dose, was able to reduce the inflammatory response to the infection to levels similar to those with azoles (33), although a total cure in patients with CBM remains difficult to achieve (26, 34). On the other hand, various formulations of amphotericin B have been developed and are now available in most countries (35). The compound is nevertheless not recommended as a first-line therapy in chronic infections because of its adverse effects, such as nephrotoxicity, neurotoxicity, hematological side effects, and allergic reactions (36). However, the use of combination therapy can reduce cost- and toxicity-related effects and may prevent the emergence of resistance (35). Combination therapy is also recommended in salvage therapy scenarios for patients with antifungal-resistant and invasive refractory mycoses (37). Few studies have reported data on the efficacy of antifungal combination therapy in the treatment of severe and refractory CBM. Treatment with amphotericin B and a subsequent combination of flucytosine and itraconazole was shown to be effective in a patient with a CBM-like infection caused by *P. verrucosa* (23). Combinations of itraconazole with flucytosine (24, 25) and itracona-

zole with terbinafine have also shown better efficacy than monotherapy for CBM caused by *F. pedrosoi* (26) and *F. monophora* (38). In general, however, combination therapy still is inadequate, requiring long-term therapy at high doses, and treatment failure of CBM remains common. The *in vitro* results obtained in the present study confirmed that terbinafine is active against the majority of strains tested. Of the nine species investigated, *Cladophialophora carrionii* and *Phialophora verrucosa* were more sensitive to terbinafine than species of *Fonsecaea* and *Exophiala*. The three species of *Fonsecaea* showed similar degrees of susceptibility. As in previous reports (39–41), in our study, *E. spinifera* and *V. botryosa* were resistant to terbinafine and amphotericin B when used alone. Although a synergistic interaction was found in a combination setting for *E. spinifera*, the combination of terbinafine and amphotericin B exhibited an indifferent interaction for tested isolates of *Veronaea botryosa*. In the current study, a wide range of amphotericin B MICs (0.125 to >8 μg/ml) was observed for agents of CBM. *Exophiala dermatitidis* and *P. verrucosa* were the species being relatively susceptible, which is in agreement with previous studies (27, 42). When terbinafine and amphotericin B were used in combination, the highest synergy was shown for *F. monophora* and *E. spinifera*, followed by *E. dermatitidis*, *C. carrionii*, *F. nubica*, and *F. pedrosoi.* Our findings agree with those of Daboit et al. (43), demonstrating *in vitro* synergy between amphotericin B and terbinafine for *Fonsecaea* spp., *C. carrionii*, and *P. verrucosa*. Biancalana et al. (44) also reported 96.5% *in vitro* synergy between terbinafine and amphotericin B against clinical isolates obtained from cases of phaeohyphomycosis and CBM, including *F. pedrosoi*, *Curvularia* spp., *Exophiala jeanselmei*, *Alternaria alternata*, *Cladophialophora bantiana*, and *Bipolaris* species. In contrast, Yu et al. (45) did not find an interaction for this combination against agents for CBM.

Overall, the management of CBM is complicated and requires long-term antifungal therapy, surgery, thermotherapy, chemotherapy, or combinations of these (3). Importantly, the clinical experience with posaconazole and voriconazole is limited for CBM. However, the good *in vitro* activities and *in vivo* efficacies of these agents against dematiaceous fungi (46–48), together with the tolerance of the drug in long-term therapies, suggest that further studies are warranted to evaluate the potential use of these drugs for the treatment of CBM.

Collectively, the present study demonstrated that the combination with terbinafine allows a significant reduction in amphotericin B MICs and could be an option for severe or unresponsive cases of CBM, particularly in cases due to *Fonsecaea* and *Cladophialophora* species, and in *E. spinifera*. Our results therefore suggest that a combination of amphotericin B and terbinafine may have a promising role in the treatment of CBM.

ACKNOWLEDGMENTS

P.E.V. has served as a consultant and has received research grants from Astellas, Basilea, Gilead Sciences, Merck, and Pfizer.

We declare no conflicts of interest. We alone are responsible for the content and the writing of the paper.

This study was supported in part by the National Natural Science Foundation of China (grant 81260236), the 973 Program of China (grant 2013CB531601), National Science and Technology Major Projects of China grant 2013ZX10004612, Shanghai Science and Technology Committee grant 14DZ2272900, the Center of Excellence for Infection Biology and Antimicrobial Pharmacology, Tehran, Iran, the Department of Medical Microbiology, Radboudumc, Nijmegen, The Netherlands, and the Westerdijk Fungal Biodiversity Center, Utrecht, The Netherlands.

REFERENCES

1. Queiroz-Telles F, de Hoog S, Santos DW, Salgado CG, Vicente VA, Bonifaz A, Roilides E, Xi L, Azevedo CM, da Silva MB, Pana ZD, Colombo AL, Walsh TJ. 2017. Chromoblastomycosis. Clin Microbiol Rev 30:233–276. https://doi.org/10.1128/CMR.00032-16.
2. Bonifaz A, Carrasco-Gerard E, Saul A. 2001. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44:1–7. https://doi.org/10.1046/j.1439-0507.2001.00613.x.
3. Seyedmousavi S, Netea MG, Mouton JW, Melchers WJG, Verweij PE, de

Hoog GS. 2014. Black yeasts and their filamentous relatives: principles of pathogenesis and host defense. Clin Microbiol Rev 27:527–542. https://doi.org/10.1128/CMR.00093-13.
4. Carrión AL. 1950. Chromoblastomycosis. Ann N Y Acad Sci 50:1255–1282. https://doi.org/10.1111/j.1749-6632.1950.tb39826.x.
5. Carrión AL. 1975. Chromoblastomycosis and related infections: new concepts, differential diagnosis, and nomenclatorial implications. Int J Dermatol 14:27–32. https://doi.org/10.1111/j.1365-4362.1975.tb00074.x.
6. Queiroz-Telles F. 2015. Chromoblastomycosis: a neglected tropical disease. Rev Inst Med Trop Sao Paulo 57(Suppl 19):S46–S50. https://doi.org/10.1590/S0036-46652015000700009.
7. Sousa Mda G, Reid DM, Schweighoffer E, Tybulewicz V, Ruland J, Langhorne J, Yamasaki S, Taylor PR, Almeida SR, Brown GD. 2011. Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin. Cell Host Microbe 9:436–443. https://doi.org/10.1016/j.chom.2011.04.005.
8. Gomes RR, Vicente VA, Azevedo CM, Salgado CG, da Silva MB, Queiroz-Telles F, Marques SG, Santos DW, de Andrade TS, Takagi EH, Cruz KS, Fornari G, Hahn RC, Scroferneker ML, Caligine RB, Ramirez-Castrillon M, de Araujo DP, Heidrich D, Colombo AL, de Hoog GS. 2016. Molecular epidemiology of agents of human chromoblastomycosis in Brazil with the description of two novel species. PLoS Negl Trop Dis 10:e0005102. https://doi.org/10.1371/journal.pntd.0005102.
9. Najafzadeh MJ, Sun J, Vicente VA, Klaassen CH, Bonifaz A, Gerrits van den Ende AH, Menken SB, de Hoog GS. 2011. Molecular epidemiology of *Fonsecaea* species. Emerg Infect Dis 17:464–469. https://doi.org/10.3201/eid1703.100555.
10. de Hoog GS, Nishikaku AS, Fernandez-Zeppenfeldt G, Padin-Gonzalez C, Burger E, Badali H, Richard-Yegres N, van den Ende AH. 2007. Molecular analysis and pathogenicity of the *Cladophialophora carrionii* complex, with the description of a novel species. Stud Mycol 58:219–234. https://doi.org/10.3114/sim.2007.58.08.
11. Brischetto A, Kidd S, Baird R. 2015. First reported Australian case of *Cladophilophora arxii*: features consistent with possible primary pulmonary chromoblastomycosis. Am J Trop Med Hyg 92:791–793. https://doi.org/10.4269/ajtmh.14-0711.
12. Matsumoto T, Matsuda T, McGinnis MR, Ajello L. 1993. Clinical and mycological spectra of *Wangiella dermatitidis* infections. Mycoses 36:145–155. https://doi.org/10.1111/j.1439-0507.1993.tb00743.x.
13. Barba-Gómez JF, Mayorga J, McGinnis MR, Gonzalez-Mendoza A. 1992. Chromoblastomycosis caused by *Exophiala spinifera*. J Am Acad Dermatol 26:367–370. https://doi.org/10.1016/0190-9622(92)70058-N.
14. Takeuchi A, Anzawa K, Mochizuki T, Takehara K, Hamaguchi Y. 2015. Chromoblastomycosis caused by *Phialophora verrucosa* on the hand. Eur J Dermatol 25:274–275.
15. Zhu CY, Yang YP, Sheng P, Li W, Huang WM, Fan YM. 2015. Cutaneous chromoblastomycosis caused by *Veronaea botryosa* in a patient with pemphigus vulgaris and review of published reports. Mycopathologia 180:123–129. https://doi.org/10.1007/s11046-015-9887-0.
16. Queiroz-Telles F, Santos DW. 2013. Challenges in the therapy of chromoblastomycosis. Mycopathologia 175:477–488. https://doi.org/10.1007/s11046-013-9648-x.
17. Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. 1988. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci 544:504–516. https://doi.org/10.1111/j.1749-6632.1988.tb40448.x.
18. Bonifaz A, Saul A, Paredes-Solis V, Araiza J, Fierro-Arias L. 2005. Treatment of chromoblastomycosis with terbinafine: experience with four cases. J Dermatol Treat 16:47–51. https://doi.org/10.1080/09546630410024538.
19. Andrade TS, Castro LG, Nunes RS, Gimenes VM, Cury AE. 2004. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses 47:216–221. https://doi.org/10.1111/j.1439-0507.2004.00984.x.
20. Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A. 2009. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 47:3–15. https://doi.org/10.1080/13693780802538001.
21. Castro LG, Pimentel ER, Lacaz CS. 2003. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 years' experience. Int J Dermatol 42:408–412. https://doi.org/10.1046/j.1365-4362.2003.01532.x.
22. Bonifaz A, Martinez-Soto E, Carrasco-Gerard E, Peniche J. 1997. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int J Dermatol 36:542–547. https://doi.org/10.1046/j.1365-4362.1997.00085.x.
23. Park SG, Oh SH, Suh SB, Lee KH, Chung KY. 2005. A case of chromoblastomycosis with an unusual clinical manifestation caused by *Phialophora verrucosa* on an unexposed area: treatment with a combination of amphotericin B and 5-flucytosine. Br J Dermatol 152:560–564. https://doi.org/10.1111/j.1365-2133.2005.06424.x.
24. Antonello VS, Appel da Silva MC, Cambruzzi E, Kliemann DA, Santos BR, Queiroz-Telles F. 2010. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Rev Inst Med Trop Sao Paulo 52:329–331. https://doi.org/10.1590/S0036-46652010000600008.
25. Paniz-Mondolfi AE, Colella MT, Negrin DC, Aranzazu N, Oliver M, Reyes-Jaimes O, Perez-Alvarez AM. 2008. Extensive chromoblastomycosis caused by *Fonsecaea pedrosoi* successfully treated with a combination of amphotericin B and itraconazole. Med Mycol 46:179–184. https://doi.org/10.1080/13693780701721856.
26. Gupta AK, Taborda PR, Sanzovo AD. 2002. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by *Fonsecaea pedrosoi* in Brazil. Med Mycol 40:529–534. https://doi.org/10.1080/mmy.40.5.529.534.
27. Deng S, Pan W, Liao W, de Hoog GS, Gerrits van den Ende AH, Vitale RG, Rafati H, Ilkit M, Van der Lee AH, Rijs AJ, Verweij PE, Seyedmousavi S. 2016. Combination of amphotericin B and flucytosine against neurotropic species of melanized fungi causing primary cerebral phaeohyphomycosis. Antimicrob Agents Chemother 60:2346–2351. https://doi.org/10.1128/AAC.02526-15.
28. de Hoog GS, Guarro J, Gene J, Figueras MJ. 2009. Atlas of clinical fungi: the ultimate benchtool for diagnostics. Centraalbureau voor Schimmelcultures, KNAW Fungal Biodiversity Center/Universitat Rovira i Virgili, Utrecht, The Netherlands.
29. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and laboratory Standards Institute, Wayne, PA.
30. Hindler J. 1995. Antimicrobial susceptibility testing, p 5.18.11–15.18.20. *In* Isenberg HD (ed), Clinical microbiology procedures handbook. ASM Press, Washington, DC.
31. Berenbaum MC. 1978. A method for testing for synergy with any number of agents. J Infect Dis 137:122–130. https://doi.org/10.1093/infdis/137.2.122.
32. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37:540–545. https://doi.org/10.1128/AAC.37.3.540.
33. Calvo E, Pastor FJ, Mayayo E, Hernandez P, Guarro J. 2011. Antifungal therapy in an athymic murine model of chromoblastomycosis by *Fonsecaea pedrosoi*. Antimicrob Agents Chemother 55:3709–3713. https://doi.org/10.1128/AAC.01662-10.
34. Minotto R, Bernardi CD, Mallmann LF, Edelweiss MI, Scroferneker ML. 2001. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol 44:585–592. https://doi.org/10.1067/mjd.2001.112220.
35. Seyedmousavi S, Rafati H, Ilkit M, Tolooe A, Hedayati MT, Verweij P. 2017. Systemic antifungal agents: current status and projected future developments. Methods Mol Biol 1508:107–139. https://doi.org/10.1007/978-1-4939-6515-1_5.
36. Hamill RJ. 2013. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73:919–934. https://doi.org/10.1007/s40265-013-0069-4.
37. Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJJM, Mouton JW, Verweij PE. 2013. *In vitro* interaction of voriconazole and anidulafungin against triazole-resistant *Aspergillus fumigatus*. Antimicrob Agents Chemother 57:796–803. https://doi.org/10.1128/AAC.00980-12.
38. Zhang JM, Xi LY, Zhang H, Xie Z, Sun JF, Li XQ, Lu S. 2009. Synergistic effects of terbinafine and itraconazole on clinical isolates of *Fonsecaea monophora*. Eur J Dermatol 19:451–455. https://doi.org/10.1684/ejd.2009.0728.
39. Daboit TC, Duquia RP, Magagnin CM, Mendes SD, Castrillon MR, Steglich R, dos Santos IS, Vettorato G, Valente P, Scroferneker ML. 2012. A case of *Exophiala spinifera* infection in southern Brazil: molecular identification and antifungal susceptibility. Med Mycol Case Rep 1:72–75. https://doi.org/10.1016/j.mmcr.2012.08.006.
40. Vitale RG, Perez-Blanco M, De Hoog GS. 2009. *In vitro* activity of antifungal drugs against *Cladophialophora* species associated with human chromoblastomycosis. Med Mycol 47:35–40. https://doi.org/10.1080/13693780802566333.
41. Duarte APM, Pagnocca FC, Baron NC, Melhem MDC, Palmeira GA, de Angelis DD, Attili-Angelis D. 2013. *In vitro* susceptibility of environmental

isolates of *Exophiala dermatitidis* to five antifungal drugs. Mycopathologia 175:455–461. https://doi.org/10.1007/s11046-012-9597-9.
42. Sun Y, Liu W, Wan Z, Wang XH, Li RY. 2011. Antifungal activity of antifungal drugs, as well as drug combinations against *Exophiala dermatitidis*. Mycopathologia 171:111–117. https://doi.org/10.1007/s11046-010-9358-6.
43. Daboit TC, Massotti Magagnin C, Heidrich D, Czekster Antochevis L, Vigolo S, Collares Meirelles L, Alves K, Scroferneker ML. 2014. *In vitro* susceptibility of chromoblastomycosis agents to five antifungal drugs and to the combination of terbinafine and amphotericin B. Mycoses 57:116–120. https://doi.org/10.1111/myc.12111.
44. Biancalana FSC, Lyra L, Schreiber AZ. 2011. *In vitro* evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds. Antimicrob Agents Chemother 55:4485–4487. https://doi.org/10.1128/AAC.01015-10.
45. Yu J, Li R, Zhang M, Liu L, Wan Z. 2008. *In vitro* interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China. Med Mycol 46:745–747. https://doi.org/10.1080/13693780802163438.
46. Calvo E, Pastor FJ, Salas V, Mayayo E, Capilla J, Guarro J. 2012. Histopathology and antifungal treatment of experimental murine chromoblastomycosis caused by *Cladophialophora carrionii*. J Antimicrob Chemother 67:666–670. https://doi.org/10.1093/jac/dkr537.
47. Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. 2005. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 47:339–346. https://doi.org/10.1590/S0036-46652005000600006.
48. Bonifaz A, Paredes-Solis V, Saul A. 2004. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother 5:247–254. https://doi.org/10.1517/14656566.5.2.247.